{'en': 'Symposium in Barcelona on future diabetes therapies', 'es': 'Simposio en Barcelona sobre terapias futuras en diabetes'} Image

Symposium in Barcelona on future diabetes therapies

fer's profile photo   10/18/2017 9:33 a.m.

  
fer
10/18/2017 9:33 a.m.

More than seven hundred experts around the world will participate in the first edition of the Congress of Biochemistry and Molecular Biology of France, Portugal and Spain (Febs3+).

A high -level scientific summit that will host the Fira Palace in Barcelona from October 23 to 26, under the presidency of Professor Antonio Zorzano, of the Faculty of Biology of the University of Barcelona, ​​which is head of the group of the CIBER group of CIBER ofAssociated metabolic diabetes and diseases (CIBERDEM) at the Biomedical Research Institute (IRB Barcelona).

Within the framework of that congress, a satellite symposium on future diabetes therapies will be carried out.

This International Congress is an initiative of the French Society of Biochemistry and Molecular Biology (SFBBM), the Portuguese Society of Biochemistry and Biology (SPB) and the Spanish Society of Biochemistry and Molecular Biology (SEBBM), and has the support of the European Federationof biochemistry societies (Febs).FEBS3+ also coincides with the celebration of the XL Congress of the SEBBM, the main scientific group throughout the State within this wide field of knowledge of life sciences, created in 1963 and with about 4000 partners.

During the inaugural ceremony, scheduled on Monday 23 at 5:30 p.m.Innate immunity.In the opening ceremony, the presence of the Secretary of Universities and Research, Arcadi Navarro;and the president of Congress, Antonio Zorzano among other authorities.

CIBERDEM-MSD Satellite Symposium Future Therapies in Diabetes

Within the framework of the International Congress, a Ciberdem-MSD satellite symposium will take place on October 26 in which future diabetes therapies will be addressed.Jorge Ferrer.The session will be moderated by the scientific director of CIBERDEM, Eduard Montanya, and by Antonio Zorzano.Both entities, Ciberdem and MSD, collaborate by making training sessions for years presenting and discussing advances in diabetes from different perspectives.

The challenges of biochemistry and molecular biology in the future

«In addition to the interest of the scientific content of Congress, one of the key factors of the first edition of the Febs3+ is to be able to offer a platform for the members of the organizational entities - in concrete, SFBBM, SPB and SEBBM - to create work groups with work groups withCommon interests »Details Professor Antonio Zorzano, president of the Organizing Committee of the Febs3+ and SEBBM.

From October 23 to 26, attendees to Febs3+ will actively participate in symposia, plenary conferences, debates and working groups that will address the most significant progress and research lines today in areas of knowledge about integrative metabolism, gene regulation, cell engineering, molecular biophysics and related areas.Among other contents, the program also includes a series of plenary conferences that will teach international projection experts such as Jules Zierath (University of Copenhagen, Denmark), Carlos Bustamante (University of California, United States), Miguel Allende (University of Chile) and PabloWappner (University of Buenos Aires), among other experts.

Diabetes Tipo 1 desde 1.998 | FreeStyle Libre 3 | Ypsomed mylife YpsoPump + CamAPS FX | Sin complicaciones. Miembro del equipo de moderación del foro.

Autor de Vivir con Diabetes: El poder de la comunidad online, parte de los ingresos se destinan a financiar el foro de diabetes y mantener la comunidad online activa.

  
Emily
07/22/2018 11:39 p.m.

What year is it?I do not see the date of the post, I do not know if it is old or new.

Diabetes post quirúrgica desde el 02/03/17, Toujeo, Novorapid, y ahora también metformina después de las comidas.
Freestylelibre 2 desde mediados de diciembre 2021, que me lleva loca.

Join the Discussion!

To participate in this thread, please register or log in.